Last updated 6 months ago

Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

80 patients around the world

Available in Spain, Argentina, United States

Neurocrine Biosciences

1Research sites

80Patients around the world

This study is for people with

Dyskinesia

Cerebral Palsy

To 70 Years

All Gender

: Medically confirmed diagnosis of DCP (that is, a hyperkinetic movement disorder due to cerebral palsy [CP]) with choreiform movements.
Medical conditions are stable and expected to remain stable throughout the study.

: Are pregnant or breastfeeding.
Have a clinical diagnosis or history of dyskinesia due to condition other than CP.
Have inability to swallow soft solids, unless medications can be administered via a gastrostomy tube.
Have any suicidal behavior or suicidal ideation in the year prior to screening or on Day 1.
Is a substance abuser of any compound.
Known history of long QT syndrome or cardiac tachyarrhythmia, or clinically significant electrocardiogram (ECG) abnormalities.

Instituto de Neurología Cognitiva (INECO)

Recruiting

Marcelo Torcuato de Alvear 1632, C1021 Cdad. Autónoma de Buenos Aires, Argentina

SponsorNeurocrine Biosciences

Conditions

Requirements

To 70 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT05206513